NICE logo

BIMZELX: The first and only licensed selective IL-17A and IL-17F inhibitor for moderate-to-severe plaque psoriasis1-3

BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1

NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2

Off
EXPLORE THE STORIES
Image
Jump icon
Off
Image
Clearance
Image
Clearance

Clearance

Image
Rapidity
Image
Rapidity

Rapidity & durability

Image
Dosing
Image
Dosing

DOSING

Image
Safety
Image
Safety

Safety profile

Off

Promotional Events

On

Clearance

Image
Clearance
Image
Clearance

Clearance

On

Rapidity & Durability

Image
Rapidity
Image
Rapidity

Rapidity & durability

On

Mechanism of Action

Image
bkz-home-moa
Image
bkz-home-moa

Mechanism of action

On

Safety Profile

Image
Safety
Image
Safety

Safety profile

On

Dosing

Image
Dosing
Image
Dosing

On

Clinical trials

Image
Clinical trials
Image
Clinical trials

Clinical trials

On

Resources

Image
HCP resources
Image
HCP resources

HCP resources

Image
Payer resources
Image
Payer resources

Payer resources

Image
Patient resources
Image
Patient resources

Patient resources

On

Bimzelx Select

Image
Bimzelx select
Image
Bimzelx select

BIMZELX select

On

Medicine Optimisation

Image
bkz-home-medicine
Image
bkz-home-medicine

Medicine optimisation

On

References

References

  1. Bimzelx Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. 2021. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis.
  3. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273)487-498.
On

CHALLENGE EXPECTATIONS

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: August 2021
IE-P-BK-PSO-2100051